

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/517,446	12/09/2004	Yoshihide Ueno	0020-5328PUS1	8646	
2292 BIRCH STEW	7590 04/02/2007 ART KOLASCH & BIRCH	EXAMINER			
PO BOX 747		FREISTEIN,	FREISTEIN, ANDREW B		
FALLS CHUR	CH, VA 22040-0747		ART UNIT	PAPER NUMBER	
	•	1626			
	•				
			NOTIFICATION DATE	DELIVERY MODE	
			04/02/2007	ELECTRONIC	

Please find below and/or attached an Office communication concerning this application or proceeding.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

mailroom@bskb.com

SUPPLEMENTAL Notice of Allowability

Application No.	Applicant(s)		
10/517,446	UENO ET AL.		
Examiner	Art Unit		
Andrew B. Freistein	1626		

		1000				
	Andrew B. Freistein	1626				
The MAILING DATE of this communication appeal claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIOF the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this app or other appropriate communication IGHTS. This application is subject to	dication. If not include will be mailed in due	ed course. THIS			
1. This communication is responsive to IDS filed 2/20/07.						
2. 🔀 The allowed claim(s) is/are <u>1-7, 10, 11, 13 and 15 (now 1-</u>	<u>11)</u> .					
 3. Acknowledgment is made of a claim for foreign priority ur a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents 	e been received. e been received in Application No		tion from the			
International Bureau (PCT Rule 17.2(a)).						
* Certified copies not received:						
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		complying with the red	quirements			
4. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give			OTICE OF			
5. CORRECTED DRAWINGS (as "replacement sheets") mus	5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.					
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached						
1) 🗌 hereto or 2) 📗 to Paper No./Mail Date	,					
(b) ☐ including changes required by the attached Examiner's Paper No./Mail Date	s Amendment / Comment or in the O	ffice action of				
Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in t			back) of			
 DEPOSIT OF and/or INFORMATION about the depo attached Examiner's comment regarding REQUIREMENT 			Note the			
•						
Attachment(s)						
1. Notice of References Cited (PTO-892)	5. Notice of Informal P	atent Application				
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	 Interview Summary Paper No./Mail Dat 					
Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date <u>See Continuation Sheet</u>	7. 🛛 Examiner's Amendn					
4. Examiner's Comment Regarding Requirement for Deposit	8. X Examiner's Stateme	nt of Reasons for Allo	wance			
of Biological Material	9.					

Continuation of Attachment(s) 3. Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date: 12/09/04; 02/18/05; 02/8/07.

DETAILED ACTION

This action is in response to the IDS filed 02/08/2007. The issue fee was paid on 02/20/2007.

The amendment filed 10/20/2006 was entered. Claims 1-7, 10, 11, 13 and 15 are pending. Claims 8, 9, 12, 14 and 16 were cancelled.

Information Disclosure Statement

In the IDS filed 02/08/2007, Applicant questions why the "Foreign Patent Documents" and the "Non Patent Literature Documents" were struck and not initialed. Examiner reviewed the contents of the file and initialed the references that the USPTO received and struck the references that the USPTO did not receive. Please refer to Applicant's copies of the 1449 submitted herewith of the IDS filed 12/09/2004. Applicant declined to provide the additional references.

Restriction Requirement

The restriction requirement between products and method of treatment claims is withdrawn. However, the restriction requirement among product claims is maintained and applicant reserves the right to file one or more divisional applications on non-elected compounds.

Claim Rejections - 35 USC § 112

Claims 1-13 were rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point. As a result of the amendment filed 10/20/2006, there rejection is withdrawn.

Examiner's Amendment

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given during a telephone interview with Attorney Mark J. Nuell, Ph.D. on November 9, 2006.

This application has been amended as follows:

- 1. In claim 1, on page 2, in line 12 of the page, after, "C(=O)NR^{1a}R^{1b}, -X-R^{1e}-C(=O)OR^{1a} or -X-R^{1d} in which X is", delete "a".
- 2. In claim 15, on page 8, in the second line of the claim, after, "urination", delete "urinary incontinence, depression, or bilestone" and insert
- -- or urinary incontinence--.
- 3. In the specification, after the title and before the paragraph entitled, "Technical Field", insert the paragraph
- --This is a National filing under 35 U.S.C. § 371 of PCT/JP03/07382, filed June 10, 2003.--

Reasons For Allowance

The instant invention is a compound of formula (I), a pharmaceutical composition comprising a compound of formula (I), and a method of treating obesity, hyperglycemia, frequent urination or urinary incontinence comprising administering to a patient a compound of formula (I).

Application/Control Number: 10/517,446

Art Unit: 1626

The closest relevant art is Fisher et al., US 5030640, which discloses the

compound:

(see col. 9, Ex. 3). The prior art

Page 4

compound has a pyridinyl group substituted with an NH₂ group. However, the instant application has a pyridyl group substituted with H, halogen, or cyano and not NH₂.

Telephone Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Andrew B. Freistein whose telephone number is (571) 272-8515. The examiner can normally be reached Monday-Friday, 8:30 am - 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph M^oEKane can be reached on (571) 272-0699. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at (866) 217-9197 (toll-free).

Andrew B. Freistein Patent Examiner, AU 1626

oseph K. M[⊆]Kane

Supervisory Patent Examiner, AU 1626

Date: March 26, 2007